A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

NCT03029832 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class

Stopped The study was prematurely terminated due to slow patient accrual and discontinuation of clinical development of MOXR0916 due to Sponsor's strategic priorities.

Conditions

Interventions

Sponsor

Genentech, Inc.